Legend Biotech shares surge 40% on promising CAR‑T data
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Legend Biotech shares jumped over 40% after the company disclosed early data on its in‑vivo CAR‑T therapy.
- Legend Biotech reported that the CAR‑T therapy showed promise in treating Non‑Hodgkin’s lymphoma.
- Biotech stocks fell broadly, yet Legend Biotech surged over 40%.
Why it matters: Legend Biotech investors capture a 40%+ stock surge, while biotech peers see declines, highlighting the market premium for early CAR‑T successes and potentially drawing capital away from other biotech firms.
